Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7032MR)

This product GTTS-WQ7032MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7032MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15262MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ4515MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ11675MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ8805MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ5783MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ7789MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ5642MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ8473MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW